NCT05214794CompletedPhase 2
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 17 Jan 2022
- Start date
- 20 Apr 2022
- Primary completion date
- 4 Jun 2024
- Lead sponsor
- Maruho Co., Ltd.
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT05214794
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 6
- From 20 Apr 2022 to the primary completion date, 4 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients witg a disease considered inappropriate for participation in clinical trials, such as serious cardiac / hepatic / renal / pulmonary / hematologic disease
- Patients with a diseases that could interfere with assessment of Systemic Sclerosis
Other
- Patients with body weight less than 30.0kg
- Pregnant or lactating women.
Who the study is looking for
- Diagnosis of Systemic Sclerosis according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2013 criteria
- Systemic Sclerosis patients with moderate to sever skin sclerosis
Age in the registry: 20 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Tokyo Hospital Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.